20-30 million U.S has been flouted as the ball park figure for a regional licensing deal. This is based off of previous deals and and current bio sentiment.
So potentially 3 jurisdictions, say 20mill each for example would be the 60million he was reffering to.
I dont think a cap raise would be the worse thing if we needed to raise another 50 mill for the trial close out and NDA, if we actually get that far down the road, then the share price should be in a much better place to be able to raise cash. Thats my view on it.
Sharewise Presentation 22/7/24, page-100
-
- There are more pages in this discussion • 40 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
22.0¢ |
Change
0.005(2.33%) |
Mkt cap ! $75.23M | |||
| Open | High | Low | Value | Volume |
| 22.0¢ | 22.0¢ | 21.5¢ | $34.87K | 160.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 140877 | 21.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 22.0¢ | 34551 | 4 |
View Market Depth
| Last trade - 11.31am 08/11/2024 (20 minute delay) ? |
| PAR (ASX) Chart |